rs2227983
A SNP in the EGFR gene on chromosome 7. Its most notable genotype is G;G: common in clinvar
- Gene
- EGFR
- Location
- Chr 755,161,562 (GRCh38)
- Highest magnitude
- 0.0Typical
- Tested on
- 23andMe, AncestryDNA
- Minor allele frequency
- 30%
Genotypes
As shown in 23andMe and AncestryDNA files.
On SNPedia: (G;G). Magnitude rates how notable a genotype is from 0 to 10, not how risky it is.
Frequency
Share of each genotype in 11 HapMap populations.
- AverageG;G 55%
- European ancestry (Utah)G;G 52%
- Han Chinese (Beijing)G;G 23%
- Japanese (Tokyo)G;G 12%
- Yoruba (Nigeria)G;G 88%
- African ancestry (Southwest US)G;G 80%
- Chinese (Denver)G;G 21%
- Gujarati IndianG;G 37%
- Luhya (Kenya)G;G 94%
- Mexican ancestry (Los Angeles)G;G 50%
- Maasai (Kenya)G;G 90%
- TuscanG;G 58%
Related
Other EGFR SNPs
- rs2293347C;Camong NSCLC patients, better Gefitinib response; commonMinor
- rs763317A;A3.5x increased lung cancer risk for never-smoking femalesTypical
- rs1050171G;Gcommon in clinvarTypical
- rs2072454C;Ccommon in clinvarTypical
- rs3735061G;Gcommon in complete genomicsTypical
- rs6958497T;Tcommon in complete genomicsTypical
- rs11979158A;Acommon in complete genomicsTypical
- rs17290699A;Acommon in complete genomicsTypical
Notes
From SNPedia
Show notes, about 180 words
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. A two-stage case-control study of EGFR polymorphisms and breast cancer risk. EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Development of a fingerprinting panel using medically relevant polymorphisms. Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia. Population based allele frequencies of disease associated polymorphisms in the Personalized Medicine Research Project. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Source and license
Adapted from rs2227983 on SNPedia, using a snapshot taken October 16, 2026. SNPedia content is shared under CC BY-NC-SA 3.0 US, and this page is shared under the same license.
SNPedia is a community-edited wiki. Its entries can be incomplete, out of date or wrong, and nothing here is a diagnosis or medical advice. Magnitude is a community rating of how interesting a genotype is, not a risk score.